purpos
studi
detect
chang
coagul
fibrinolysi
postsever
acut
respiratori
syndrom
sar
chines
patient
osteonecrosi
investig
aetiolog
postsar
osteonecrosi
select
sensit
molecular
marker
identifi
suscept
popul
studi
blood
sampl
collect
patient
postsar
healthi
peopl
spring
sever
acut
respiratori
syndrom
sar
spread
china
save
live
patient
high
dose
corticosteroid
use
consequ
mani
patient
osteonecrosi
found
period
rehabilit
aetiolog
pathogenesi
nontraumat
still
fulli
understood
hypothesi
intravascular
coagul
like
final
common
pathway
nontraumat
recent
gain
support
relat
underli
thrombophilia
hypofibrinolysi
intravascular
coagul
intermediari
event
alway
activ
underli
risk
factor
past
studi
limit
western
popul
question
whether
differ
present
eastern
western
popul
therefor
studi
chang
coagul
fibrinolysi
chines
patient
postsar
order
compar
chang
two
ethnic
group
decemb
march
patient
demonstr
osteonecrosi
hip
knee
joint
magnet
reson
imag
mri
includ
studi
group
group
healthi
individu
serv
control
group
group
ii
definit
diagnosi
establish
orthopaed
surgeon
radiologist
studi
group
men
women
mean
age
year
rang
mean
accumul
dose
corticosteroid
convert
methylprednison
mg
rang
mean
maximum
daili
dose
mg
rang
mean
durat
corticosteroid
administr
day
rang
found
hip
patient
bilater
knee
nine
patient
five
bilater
patient
character
multifoc
three
anatom
site
one
patient
bone
infarct
detect
shaft
femur
control
group
compos
healthi
cohort
medic
staff
men
women
mean
age
year
rang
fast
blood
sampl
cubit
vein
collect
group
subject
seat
min
ml
venou
blood
collect
vacutain
tube
contain
sodium
citrat
vacuett
china
anoth
ml
collect
vacutain
tube
contain
ethylenediaminetetraacet
edta
vacuett
china
analys
homocystein
hci
must
centrifug
within
h
volum
ratio
anticoagul
solut
blood
blood
sampl
centrifug
g
min
room
temperatur
plateletpoor
plasma
snapfrozen
store
coagulomet
stacompact
franc
use
analys
factor
accord
kit
instruct
staliatest
diagnostica
stago
franc
protein
c
pc
antithrombin
iii
atiii
plasminogen
activ
inhibitor
pai
activ
protein
c
resist
apcr
plasminogen
plg
von
willebrand
factor
vwf
ddimer
dd
homocystein
hci
examin
enzymelink
immunosorb
assay
elisa
activ
partial
thromboplastin
time
aptt
analys
twostep
techniqu
fibrinogen
fib
analys
accord
method
clauss
level
test
result
shown
mean
standard
deviat
mani
data
normal
distribut
comparison
two
group
perform
wilcoxon
nonparametr
test
chisquar
test
use
analyz
member
abnorm
statist
signific
accept
p
level
sa
spss
use
statist
blood
agent
postsar
patient
chang
obvious
patient
postsar
found
least
one
coagulopathi
versu
control
p
pc
apcr
atiii
pai
plg
significantli
differ
two
group
tabl
postsar
patient
may
caus
corticosteroid
howev
whether
sar
coronari
viru
effect
resolv
recent
mani
paper
describ
relationship
viru
patient
human
immunodefici
viru
hiv
infect
miller
studi
asymptomat
hivinfect
adult
ageand
sexmatch
hivneg
control
hivposit
group
diagnos
detect
mri
wherea
case
hivneg
group
risk
factor
includ
lipidlow
agent
testosteron
detect
level
anticardiolipin
hivinfect
patient
recent
bottaro
postul
risk
factor
peculiar
hivinfect
individu
might
play
role
pathogenesi
includ
introduct
proteas
inhibitor
result
hyperlipidemia
presenc
anticardiolipin
antibodi
serum
lead
hypercoagul
state
immun
recoveri
vascul
studi
damag
sar
coronari
viru
caus
blood
vessel
endotheli
cell
studi
patient
extern
contributor
corticosteroid
sar
thrombophil
andor
hypofibrinolyt
coagul
disord
import
coagul
abnorm
pathogenesi
note
long
time
jone
postul
intravascular
coagul
activ
varieti
underli
diseas
like
final
common
pathway
produc
intraoss
thrombosi
necrosi
intravascular
coagul
fibrinplatelet
thrombosi
begin
vulner
subchondr
bone
microcircul
capillari
sinusoid
bed
associ
vasoconstrict
impair
secondari
fibrinolysi
starklint
found
microvascular
thrombu
avascular
necrosi
provid
evid
hypothesi
thromboticfibrinolyt
pathway
complic
process
coagulopathi
caus
intermediari
event
initi
underli
aetiolog
factor
may
revers
treatabl
irrevers
subthreshold
suprathreshold
addit
multipl
environment
genet
increas
knowledg
thromboticfibrinolyt
pathway
advanc
laboratori
test
numer
factor
identifi
exist
patient
associ
thrombophilia
increas
tendenc
thrombosi
andor
hypofibrinolysi
reduc
abil
lyse
thrombi
adult
report
studi
span
year
nilsson
describ
associ
hypofibrinolysi
glueck
van
veldhuizen
describ
associ
famili
high
level
pai
glueck
evalu
coagul
disord
adult
found
cohort
enrich
thrombot
fibrinolyt
risk
factor
major
postsar
patient
tendenc
develop
thrombophilia
hypofibrinolysi
may
predispos
thrombot
venou
occlus
bone
lead
intramedullari
hypertens
anoxia
ischaem
bone
death
characterist
cosgriff
report
steroid
treatment
place
patient
prethrombot
state
patient
coagul
abnorm
higher
risk
effect
steroid
treatment
term
second
hit
theori
initi
thrombosi
research
postsar
patient
found
least
one
abnorm
coagul
fibrinolysi
factor
pc
apcr
atiii
pai
plg
significantli
differ
two
group
similar
studi
jone
et
al
glueck
et
al
effect
thromboticfibrinolyt
system
corticosteroid
treatment
transient
blood
sampl
patient
collect
six
month
stop
corticosteroid
therapi
therefor
coagul
disord
must
herit
acquir
studi
genet
mutat
thrombosi
hypofibrinolysi
unaffect
environment
vector
prove
moreov
research
sar
patient
without
enrich
understand
aetiolog
pathogenesi
nontraumat
howev
object
reason
blood
sampl
postsar
nonosteonecrosi
patient
difficult
obtain
tri
best
advanc
studi
relationship
coagulopathi
controversi
may
differ
western
eastern
popul
lee
korea
investig
consecut
patient
diagnos
nontraumat
femor
head
match
control
subject
data
confirm
aetiolog
role
thrombot
fibrinolyt
disord
east
asian
patient
nontraumat
femor
head
thought
differ
may
explain
ethnic
differ
research
support
opinion
zheng
et
al
studi
earli
late
stage
chines
patient
found
blood
chang
patient
thought
thrombophilia
hypofibrinolysi
present
everi
stage
patient
china
coagul
abnorm
control
group
least
one
abnorm
use
ten
test
assess
thrombophilia
hypofibrinolysi
cutoff
base
percentil
healthi
popul
surprisingli
high
percent
abnorm
find
control
recent
mont
et
al
studi
risk
factor
pulmonari
emboli
total
hip
knee
arthroplasti
serolog
measur
five
gene
associ
thrombophilia
andor
hypofibrinolysi
assess
control
group
also
least
one
abnorm
studi
detect
coagul
abnorm
small
proport
patient
may
reflect
limit
understand
caus
thrombosi
hypofibrinolysi
patient
categor
normal
may
shown
abnorm
test
coagul
carri
also
possibl
case
coagul
factor
abnorm
transient
make
difficult
detect
conclus
find
hypercoagul
hypofibrinolysi
postsar
chines
patient
osteonecrosi
hypercoagul
hypofibrinolysi
examin
use
screen
popul
high
risk
osteonecrosi
measur
aptt
pc
atiii
pai
apcr
plg
sensit
blood
test
screen
highrisk
popul
presum
thrombophilia
andor
hypofibrinolysi
caus
possibl
correct
patient
coagul
disord
thu
retard
progress
revers
process
preliminari
screen
patient
requir
corticosteroid
treatment
system
lupu
erythematosu
organ
transplant
nephropathi
etc
may
increas
patient
physician
awar
detect
popul
suscept
regular
mribon
scan
screen
patient
earlier
surgic
manag
improv
prognosi
anticoagul
medic
lipidclear
agent
patient
receiv
corticosteroid
prevent
onset
